PA1195XC Octreotide antigen
see all 3 Octreotide products
25 mg / please contact our distributor
NOVUS BIOLOGICALS
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
PO Box 802 Littleton, CO 80160, USA
E-Mail: novus@novus-biologicals.com
Homepage: http://www.novus-biologicals.com
Quick Overview
Human Octreotide
Product Description
Human Octreotide
Properties
| Presentation | Purified |
| Species | Human |
| Purity | >98% |
| Source | Synthetic |
| Catalog Number | PA1195XC |
| Quantity | 25 mg |
| Price | please contact our distributor |
| Delivery | Worldwide |
| Manufacturer | Acris Antibodies GmbH |
| Datasheet | view  PA1195XC.pdf |
Datasheet Extract
| Concentration | 1.0 mg/ml |
| Background | Octreotide acetate is a longer acting synthetic octapeptide analog of naturally occurring somatostatin. It inhibits the secretion of gastro-entero-pancreatic peptide hormones and the release of growth hormone. |
| Format | State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: Greater than 98.0% as determined by: (a) Analysis by RP-HPLC. (b) Anion-exchange FPLC. (c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel. BufferSystem: Octreotide was lyophilized from a concentrated solution with no additives. Reconstitution: It is recommended to reconstitute the lyophilized Octreotide in sterile 18M?-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. |
| Description | Synthetic Human Octreotide is a single, non-glycosylated, polypeptide chain containing 8 amino acids, having a molecular formula of C49H66N10O10S2 .
Octreotide is purified by proprietary chromatographic techniques. AASequence: The sequence was determined to be H-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-L-threoninol. Molecular weight: 1019.26 Dalton |
| Storage | Lyophilized Octreotide although stable at room temperature, should be stored desiccated below 0°C. Reconstituted Octreotide is best stored refrigerated at 4°C. Please avoid freeze-thaw cycles. |
| References | 1. The role of octreotide versus placebo in the prevention of post-ERCP pancreatitis.
Hepatogastroenterology 2007 Jan-Feb;54(73):250-3 2. Octreotide for esophageal variceal bleeding treated with endoscopic sclerotherapy: a randomized, placebo-controlled trial. Hepatogastroenterology 2007 Jan-Feb;54(73):195-200 3. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007 Apr;48(4):508-18 4. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007 Mar;132(3):1104-16 5. Administration of octreotide for management of postoperative high-flow chylothorax. Ann Vasc Surg 2007 Jan;21(1):90-2 6. Octreotide LAR for severe obscure-overt gastrointestinal haemorrhage in high-risk patients on anticoagulation therapy. Gut 2007 Mar;56(3):447 |
